Official UK procurement notice
NHS National Framework for the supply of Tocilizumab Injection
Authority: NHS England (Central government)
What is being bought
Published requirement descriptionProject title: NHS National Framework for the supply of Tocilizumab Injection - 01 March 2026
Offer reference number: CM/TNS/25/5723
Period of framework: 1 March 2026 to 31 August 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
CPV: Pharmaceutical products
How this framework works
From the published notice- Type
- Closed framework
- Call-offs
- every call-off is a further competition among the appointed suppliers
- Bids received
- 3 bids received · 3 suppliers appointed
- Framework period
- 1 yr 6 mo · up to 3 yrs 6 mo from 1 Mar 2026
- Buyer regions
- UKC, UKD, UKF, UKG, UKH, UKJ, UKK
Who may buy through it
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points.
Published description of the framework
Please refer to the ITO Documents for the Operation Description
The lotProcurement structure
single lot · value publishedLot #1AwardedRenewalPublished value£188,195,000
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Published sub-criteria (1)
- Price is not the only award criterion: 100%
Published award criteria (1)
- Price is not the only award criterion
- Price carries 100 of 100 points: a 10% discount moves about 10 points. This one is won on the number: sharpen the price before polishing the prose.
- “NHS National Framework for the supply of Tocilizumab Injection” is a framework: the contest is a place on its panel, not a single contract: each call-off is a further competition, so the pricing contest starts after appointment.
Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.
Procedure terms & legal framework
From the official record- Procedure method
- Open procedure
- Legal basis
- UKPGA · 2023/54 Procurement Act 2023
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Above threshold (FTS publication)
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points.
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 1 Sept 2025, 14:23 BST
- Last source update
- 30 Dec 2025, 16:27 GMT
- Award evaluation window
- Submission end – 27 Nov 2025
- Authority reference
C386455- FTS notice number
2025/S 000-063037- Latest notice
- Contract details notice (UK7)
- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-059160Find a Tender
How it was run
Official notice- Appointment period ends
- 5 Nov 2025, 13:00 GMT
- Clarification deadline
- 29 Oct 2025, 13:00 GMT
- Submission channel
- Official e-sourcing portal
- Electronic submission
- Allowed
- Accepted languages
- en
The procurement documents are available for unrestricted and full direct access, free of charge at health-family.force.com/s/Welcome ↗
Additional info obtained from the abovementioned address
Tenders must be submitted to the abovementioned address
Timeline
1 Sept 2025 → 1 Mar 2026 · 11 dates- Planning notice published1 Sept 2025, 14:23 BST
- Market engagement397 days ago19 Sept 2025, 23:59 BST
NHS England is seeking to engage with suppliers that are planning to launch Tocilizumab Injection. Interested suppliers will be invited to a virtual PME meeting to be held on 19th September 2025
The purpose of these sessions is to update suppliers regarding timelines and to discuss product details, product launches during the proposed framework period, tender structure, and KPl's.
Please contact [email protected] or [email protected] to register your interest in tendering for this framework.
- Next notice expected380 days ago6 Oct 2025, 23:59 BST
- Tender notice published379 days ago7 Oct 2025, 17:16 BST
- Clarification questions by357 days ago29 Oct 2025, 13:00 GMT
- Admission / appointment period ends350 days ago · period end, not a bid countdown5 Nov 2025, 13:00 GMT
- Assessment summaries sent329 days ago27 Nov 2025
- Award decision expected by328 days ago27 Nov 2025, 23:59 GMT
- Standstill ends316 days ago9 Dec 2025, 23:59 GMT
- Latest notice published295 days ago30 Dec 2025, 16:27 GMT
- Contract starts235 days ago1 Mar 2026
Notice history
10 events · 4 releases on Find a Tender · since 1 Sept 2025- Preliminary market engagement notice published1 Sept 2025, 14:23 BSTUK2
- Tender notice published7 Oct 2025, 17:16 BSTUK4
- Published value updated to £188,195,0007 Oct 2025, 17:16 BSTwas £231,000,000
- Status changed to active7 Oct 2025, 17:16 BST
- Procurement method changed7 Oct 2025, 17:16 BST
- Deadline published: 5 Nov 2025, 13:00 GMT7 Oct 2025, 17:16 BST
- Contract award notice published27 Nov 2025, 14:29 GMTUK6
- Status changed to complete27 Nov 2025, 14:29 GMT
- Contract signature expected22 Dec 2025, 23:59 GMTscheduled
- Contract details notice published30 Dec 2025, 16:27 GMTUK7
Routine re-releases (4)
- 2025-09: 1 release · 1 Sept 2025
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Celltrion Healthcare United Kingdom Limited, Fresenius Kabi Limited, Roche Products LtdLot 1 - CM/TNS/25/57231 Mar 2026 – 31 Aug 2027 · up to 31 Aug 2029Extensions: Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months | £150,085,000 | 26 Nov 2025standstill to 9 Dec 2025 | Standstill |
Contracts
Lot 1 - CM/TNS/25/5723
- Signed
- 12 Dec 2025
- Value
- £150,085,000
- Period
- 1 Mar 2026 – 31 Aug 2027 · up to 31 Aug 2029 with extensions
- Status
- active
- Extensions
- Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 3final-stage tenders | 0 | 0 | — |
Who bid
- wonCelltrion Healthcare United Kingdom Limited · Greater London
- wonFresenius Kabi Limited · North West England
- wonRoche Products Ltd · East of England
Bidders as named on the Procurement Act 2023 award notice. “Won” means the bidder holds an award on this notice.
Contracting authority & participating public bodies
Framework contractors & participating bidders
3 commercial parties on the notice- Celltrion Healthcare United Kingdom LimitedFramework contractor
- Fresenius Kabi LimitedFramework contractor
- Roche Products LtdFramework contractor
Official documents & specifications (17)
Official links; attachments are not copiedTender pack and attachments
- Bidding documents and specifications
- Bidding documents and specifications
- Bidding documents and specifications
- Bidding documents and specifications
- Bidding documents and specifications
- Bidding documents and specifications
- Bidding documents and specifications
- Bidding documents and specifications
Show 5 more documents
- Bidding documents and specifications
- Signed contract CONTRACT COPY UK7 Contract Details Notice - CM-TNS-25-5723 Tocilizumab
- Bidding documents and specifications
- Bidding documents and specifications
- Bidding documents and specifications
Notices published for this procedure
- Contract details notice Contract details notice on Find a Tender
- Contract award notice Contract award notice on Find a Tender
- Tender notice Tender notice on Find a Tender
- Preliminary market engagement notice Preliminary market engagement notice on Find a Tender